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Abstract
Background: Therapeutic drug monitoring (TDM) is essential practice when dosing drugs with a narrow therapeutic
index in order to achieve a plasma drug concentration within a narrow target range above the efficacy concentration
but below the toxicity concentration. However, TDM with dose individualisation is challenging during a double-blind
clinical trial with laboratory staff and investigators blinded to treatment arm allocation.
Methods: Drug concentrations were simulated for participants in the placebo arm by an unblinded independent
statistician, utilising the measured values from the treatment arm participants. Simulated and actual concentrations
were re-blinded and passed on to a dose-adjusting investigator, who made dose adjustment recommendations but
was not directly responsible for clinical care of participants.
Results: A total of 257 sham lithium plasma concentrations were simulated utilising 242 true lithium plasma
concentrations in real time as the trial progressed. The simulated values had a median (interquartile range)
of 0.59 (0.46, 0.72) compared to 0.53 (0.39, 0.72) in the treatment arm. Blinding of the laboratory staff and
dose-adjusting investigator was maintained successfully.
Conclusions: We succeeded in simulating sham lithium plasma concentrations while maintaining blinding. Our
simulated values have a smaller range than the observed data, which can be explained by the challenges with
respect to drug adherence and dose timing that were experienced.
Trial registration: Pan African Clinical Trials Registry, PACTR201310000635418. Registered on 30 August 2013.
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Background
Therapeutic drug monitoring (TDM) is essential when
dosing drugs with a narrow therapeutic index to achieve
a plasma drug concentration within a narrow target range
that is above the efficacy concentration but below the tox-
icity concentration. However, TDM with dose individual-
isation is challenging during a double-blind clinical trial
with both laboratory staff and investigators blinded to
treatment arm allocation. We report our experience of
simulating TDM results for dose individualisation by an
investigator while maintaining blinding in a double-blind,
placebo-controlled, randomised trial (RCT). The trial eval-
uated the 24-week efficacy and safety of lithium in patients
with moderate to severe HIV-associated neurocognitive
disorder (HAND). The trial was conducted in response
to the rising overall prevalence of HAND [1, 2]. Prelim-
inary data suggested that lithium may provide clinical
benefit as an adjunctive treatment in patients estab-
lished on ART [3]. Lithium has a narrow therapeutic
index (0.6–1.0 mmol/L), and the study team had to per-
form lithium TDM and individualise dosing in conjunc-
tion with participant adverse events, while maintaining
investigator blinding [4].
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Methods
The RCT methods, patient population, and primary out-
comes are described elsewhere [5], but briefly, this was a
24-week, two-arm, placebo-controlled phase IIb trial to
study lithium as an adjunctive pharmacotherapy in indi-
viduals with moderate to severe HAND. Participants
were individually randomised to either a placebo or lith-
ium arm using block randomisation prior to the start of
the study. Lithium plasma concentrations were measured
in all participants irrespective of treatment allocation at
scheduled study visits.
Blinding process
The laboratory reported all concentrations directly to
the study statistician; placebo concentrations were re-
ported as lower than the limit of detection. The study
statistician simulated sham plasma drug concentrations,
as detailed below, and provided re-blinded results to the
dose-adjusting investigator, who individualised lithium
dosing in conjunction with adverse event reports contain-
ing causality assessment and severity grading. Lithium was
titrated to achieve a target plasma concentration between
0.6 and 1.0 mmol/L, aiming for 20 mg/kg/day, as per
study protocol.
The dose-adjusting investigator was not directly involved
in participant care and received adverse event reports
from other investigators. Dosing was adjusted in order
to achieve target serum concentrations assuming linear
lithium pharmacokinetics. When significant adverse events
were considered to be related to the study drug, doses were
not upward adjusted, even when concentrations were below
0.6 mmol/L. When concentrations were below 0.6 mmol/L
at usual therapeutic doses of lithium (regarded to be be-
tween 500 to 1500 mg daily) and upward adjustment was
felt to be unsafe, a note was sent to the investigators to
confirm adherence without dose adjusting.
The study investigators who were involved in partici-
pant care, the laboratory staff, and the dose-adjusting in-
vestigator (who was not involved in participant care)
remained blinded until study close. The statistician was
not blinded, as unblinding was required in order to carry
out statistical procedures. The statistician communicated
with the dose-adjusting investigator through template
emails and never communicated with the blinded study
investigators.
Statistical methods
There was minimal data available prior to trial initiation
on normal or reference ranges for plasma lithium con-
centrations in this population, so the decision was made
to use trial-collected data in real time to set model pa-
rameters. Mean and standard deviation were estimated
from available plasma lithium concentrations measured
in the treatment arm and sham values sampled from a
Gaussian distribution based on those estimates. Rejection
sampling was used to ensure simulated values were inside
the therapeutic range of 0.6–1.0 mmol/L. The 0.6 mmol/L
threshold was modified in consultation with the Data
Safety and Monitoring Board to a lower threshold of
0.3 mmol/L after poor adherence in the treatment arm as
well as lower than expected concentrations became appar-
ent. Plasma lithium concentrations were reported in a sin-
gle file with no treatment arm information and included
the concentrations as received for the treatment arm (in-
cluding those below the assay limit of detection) and the
sham values for the placebo arm.
The study was approved by the human research ethics
committees of the University of Cape Town (071/2013)
and Stellenbosch University (M13/07/027) and regis-
tered on the Pan African Clinical Trials Registry
(PACTR201310000635418).
Results
A total of n = 257 sham lithium plasma concentrations
were simulated, with an overall median (interquartile
range, IQR) of 0.59 (0.46, 0.72) mmol/L compared to the
n = 242 observed measurements in the treatment arm
with median (IQR) 0.53 (0.39, 0.72) mmol/L. The scatter
plot and density estimates by arm are given in Fig. 1.
The dose-adjusting investigator made dose-change rec-
ommendations to increase or decrease the dose on a
total of 182 occasions (55% (n = 100) in the treatment arm
vs 45% (n = 82) in the placebo arm). Dose decreases were
recommended 33 times (54% (n = 18) vs 45% (n = 15)) and
dose increases recommended 149 times (54% (n = 82)
vs 45% (n = 67)) in the treatment and placebo arms re-
spectively. Adverse events and poor adherence records,
as reported in [5], were evenly distributed by treatment
arm.
Discussion
We succeeded in simulating sham lithium plasma con-
centrations while maintaining blinding, as evidenced by
similar rates of dose adjustments in each arm. Our simu-
lated values have a smaller range than the observed data,
which can be explained by the challenges that we en-
countered. Early adjustment of the lower bound of the
simulated range to account for non-adherence in the
treatment arm was required to prevent inadvertent
unblinding of the dose-adjusting investigator. However,
the implications of simulating data that would initiate an
intervention (in this case counselling regarding adher-
ence) for participants who may have been fully adherent
prevented adjustment to the full range of observed con-
centrations. The observed concentration range can be
explained by both low adherence and sub-optimal dose
timing. Ideally, lithium TDM should be performed as a
trough concentration just prior to the next dose being
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given, but this was not always the case due to partici-
pants not always arriving on time for their appoint-
ments. Our simulation procedure has a number of
limitations. First, we did not generate sham adverse
event reports, as we reasoned that dose individualisation
in response to sham adverse event report may poten-
tially jeopardise efficacy and increase risk. Second, it
would have been ideal to simulate individual time trajec-
tories instead of independently simulated values at each
time point. However, with sparse data available, this was
not feasible. In settings where the data to be simulated is
better described, this may be possible and desirable.
Trial processes and procedures must be adjusted to take
real-time feedback into account, and in particular, this
process required constant availability by the statistician. In
practice, especially with trials of longer duration, multiple
persons must be identified who can carry out the proced-
ure in the event of absence of the primary statistician. The
other possibility is to develop a semi-automated procedure
by using some of the new programming tools, for ex-
ample, the ‘Shiny’ package in R [6], which allows for inter-
active interfaces to R software via a website.
The balance between maintaining blinding in RCTs
and patient safety must always err towards patient safety,
and we have demonstrated a feasible method of main-
taining investigator blinding while allowing for TDM
and dose individualisation. Rapid response and willing-
ness to modify protocol must be considered in light of
trial data in order to maintain effective blinding.
Conclusions
The balance between maintaining blinding in RCTs and
patient safety must always err towards patient safety,
and we have demonstrated a feasible method of main-
taining investigator blinding while allowing for TDM
and dose individualisation. Rapid response and willing-
ness to modify protocol must be considered in light of
trial data in order to maintain effective blinding.
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Fig. 1 Observed plasma lithium concentrations in individuals randomised to treatment arm (orange circles) and sham lithium concentrations
simulated for individuals randomised to placebo arm (blue triangles) by date of sample. Solid horizontal lines represent therapeutic range; dashed
horizontal line represents adjusted lower threshold. Distribution of simulated and measured lithium concentration density estimates provided as
marginal plot (dashed = placebo; solid = lithium)
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